Laboratory diagnosis of the antiphospholipid syndrome

Thrombosis Research

Volumn 108, Issue 5-6, 2002, Pages 263-271

  Wisløff, Finn ^a   Jacobsen, Eva M ^a   Liestøl, Sigurd ^a  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

BETA2 GLYCOPROTEIN 1; BETA2 GLYCOPROTEIN 1 ANTIBODY; BLOOD CLOTTING FACTOR 9; CARDIOLIPIN; HEPARIN; HIGH MOLECULAR WEIGHT KININOGEN; LIPOCORTIN 5; PHOSPHOLIPID; PHOSPHOLIPID ANTIBODY; PROTEIN C; PROTEIN S; PROTHROMBIN;

ACTIVATED PROTEIN C RESISTANCE; ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; AUTOIMMUNITY; BLOOD CLOTTING; CARDIOVASCULAR RISK; CELL ACTIVATION; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; ENDOTHELIUM CELL; FIBRINOLYSIS; HUMAN; IMMUNOASSAY; INTERMETHOD COMPARISON; MONOCYTE; PATHOGENICITY; REVIEW; THROMBIN TIME; THROMBOCYTE; THROMBOCYTOPENIA; VEIN THROMBOSIS; BLOOD; BLOOD CLOTTING TEST; DIAGNOSIS, MEASUREMENT AND ANALYSIS; METHODOLOGY; PRACTICE GUIDELINE; STANDARD;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; BLOOD COAGULATION TESTS; HUMANS; IMMUNOASSAY; LABORATORY TECHNIQUES AND PROCEDURES; PRACTICE GUIDELINES;

EID: 0037492333     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(02)00400-0     Document Type: Review

References (102)

1. Conley C.L., Hartmann R.C. A hemorrhagic disorder caused by circulating anticoagulant in patients with disseminated lupus erythematosus. J. Clin. Invest. 31:1952;621-622.
2. Feinstein D.I., Rapaport S.I. Acquired inhibitors of blood coagulation. Prog. Hemostasis Thromb. 1:1972;75-95.
3. Bowie E.J., Thompson J.H., Pascuzzi C.A., Owen C.A. Thrombosis in systemic lupus erythematosus despite circulating anticoagulant. J. Lab. Clin. Med. 62:1963;416-430.
4. Thiagarajan P., Shapiro S.S., De Marco L. Monoclonal immunoglobulin M lambda coagulation inhibitor with phospholipid specificity. Mechanism of a lupus anticoagulant. J. Clin. Invest. 66:1980;397-405.
5. Harris E.N., Gharavi A.E., Boey M.L., Patel B.M., Mackworth-Young C.G., Loizou S.et al. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet. 2:1983;1211-1214.
6. Loizou S., McCrea J.D., Rudge A.C., Reynolds R., Boyle C.C., Harris E.N. Measurement of anti-cardiolipin antibodies by an enzyme-linked immunosorbent assay (ELISA): standardization and quantitation of results. Clin. Exp. Immunol. 62:1985;738-745.
7. Triplett D.A., Brandt J.T., Musgrave K.A., Orr C.A. The relationship between lupus anticoagulants and antibodies to phospholipid. JAMA. 259:1988;550-554.
8. McNeil H.P., Simpson R.J., Chesterman C.N., Krilis S.A. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). PNAS (USA). 87:1990;4120-4124.
9. Galli M., Comfurius P., Maassen C., Hemker H.C., de Baets M.H., Breda-Vriesman P.J.et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet. 335:1990;1544-1547.
10. Bevers E.M., Galli M., Barbui T., Comfurius P., Zwaal R.F. Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb. Haemost. 66:1991;629-632.
11. Galli M., Comfurius P., Barbui T., Zwaal R.F., Bevers E.M. Anticoagulant activity of beta 2-glycoprotein I is potentiated by a distinct subgroup of anticardiolipin antibodies. Thromb. Haemost. 68:1992;297-300.
12. Arnout J., Wittevrongel C., Vanrusselt M., Hoylaerts M., Vermylen J. Beta-2-glycoprotein I dependent lupus anticoagulants form stable bivalent antibody beta-2-glycoprotein I complexes on phospholipid surfaces. Thromb. Haemost. 79(1):1998;79-86.
13. Simmelink M.J., Horbach D.A., Derksen R.H., Meijers J.C., Bevers E.M., Willems G.M.et al. Complexes of anti-prothrombin antibodies and prothrombin cause lupus anticoagulant activity by competing with the binding of clotting factors for catalytic phospholipid surfaces. Br. J. Haematol. 113:2001;621-629.
14. Levine J.S., Branch D.W., Rauch J. The antiphospholipid syndrome. NEJM. 346(10):2002;752-763.
15. Sherer Y., Shoenfeld Y. Antiphospholipid syndrome: insights from animal models. Curr. Opin. Hematol. 7(5):2000;321-324.
16. Wilson W.A., Gharavi A.E., Koike T., Lockshin M.D., Branch D.W., Piette J.C.et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum. 42(7):1999;1309-1311.
17. Lockshin M.D., Sammaritano L.R., Schwartzman S. Validation of the Sapporo criteria for antiphospholipid syndrome. Arthritis Rheum. 43(2):2000;440-443.
18. Cervera R., Piette J.C., Font J., Khamashta M.A., Shoenfeld Y., Camps M.T.et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1000 patients. Arthritis Rheum. 46(4):2002;1910-1927.
19. Love P.E., Santoro S.A. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders, Prevalence and clinical significance. Ann. Intern. Med. 112(9):1990;682-698.
20. Alarcon-Segovia D., Perez-Vazquez M.E., Villa A.R., Drenkard C., Cabiedes J. Preliminary classification criteria for the antiphospholipid syndrome within systemic lupus erythematosus. Semin. Arthritis Rheum. 21(5):1992;275-286.
21. Wahl D.G., Guillemin F., de Maistre E., Perret C., Lecompte T., Thibaut G. Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus - a meta-analysis. Lupus. 6(5):1997;467-473.
22. Schulman S., Svenungsson E., Granqvist S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group. Am. J. Med. 104(4):1998;332-338.
23. Kearon C., Gent M., Hirsh J., Weitz J., Kovacs M.J., Anderson D.R.et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. NEJM. 340(12):1999;901-907.
24. Vaarala O., Manttari M., Manninen V., Tenkanen L., Puurunen M., Aho K.et al. Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation. 91(1):1995;23-27.
25. Brey R.L., Abbott R.D., Curb J.D., Sharp D.S., Ross G.W., Stallworth C.L.et al. Beta(2)-Glycoprotein 1-dependent anticardiolipin antibodies and risk of ischemic stroke and myocardial infarction: the Honolulu heart program. Stroke. 32(8):2001;1701-1706.
26. Levine S.R., Brey R.L., Joseph C.L., Havstad S. Risk of recurrent thromboembolic events in patients with focal cerebral ischemia and antiphospholipid antibodies. The Antiphospholipid Antibodies in Stroke Study Group. Stroke. 23(Suppl. 2):1992;S32.
27. Ginsburg K.S., Liang M.H., Newcomer L., Goldhaber S.Z., Schur P.H., Hennekens C.H.et al. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann. Intern. Med. 117(12):1992;997-1002.
28. Ginsberg J.S., Wells P.S., Brill-Edwards P., Donovan D., Moffatt K., Johnston M.et al. Antiphospholipid antibodies and venous thromboembolism. Blood. 86:1995;3685-3691.
29. Horbach D.A., van Oort E., Donders R.C., Derksen R.H., de Groot P.G. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Comparison between different assays for the detection of antiphospholipid antibodies. Thromb. Haemost. 76(6):1996;916-924.
30. Galli M., Finazzi G., Bevers E.M., Barbui T. Kaolin clotting time and dilute Russell's viper venom time distinguish between prothrombin-dependent and beta 2-glycoprotein I-dependent antiphospholipid antibodies. Blood. 86(2):1995;617-623.
31. Pengo V., Biasiolo A., Brocco T., Tonetto S., Ruffatti A. Autoantibodies to phospholipid-binding plasma proteins in patients with thrombosis and phospholipid-reactive antibodies. Thromb. Haemost. 75(5):1996;721-724.
32. Galli M., Finazzi G., Norbis F., Marziali S., Marchioli R., Barbui T. The risk of thrombosis in patients with lupus anticoagulants is predicted by their specific coagulation profile. Thromb. Haemost. 81(5):1999;695-700.
33. Pengo V., Biasiolo A., Rampazzo P., Brocco T. dRVVT is more sensitive than KCT or TTI for detecting lupus anticoagulant activity of anti-beta2-glycoprotein I autoantibodies. Thromb. Haemost. 81(2):1999;256-258.
34. Pengo V., Brocco T., Biasiolo A., Rampazzo P., Carraro P., Zamarchi R. Procoagulant effect of anti-beta2-glycoprotein I antibodies with lupus anticoagulant activity. Blood. 94(11):1999;3814-3819.
35. Le Querrec A., Arnout J., Arnoux D., Borg J.Y., Caron C., Darnige L.et al. Quantification of lupus anticoagulants in clinical samples using anti-beta2GP1 and anti-prothrombin monoclonal antibodies. Thromb. Haemost. 86(2):2001;584-589.
36. Galli M., Dlott J., Norbis F., Ruggeri L., Cler L., Triplett D.A.et al. Lupus anticoagulants and thrombosis: clinical association of different coagulation and immunologic tests. Thromb. Haemost. 84(6):2000;1012-1016.
37. Arnout J. Antiphospholipid syndrome: diagnostic aspects of lupus anticoagulants. Thromb. Haemost. 86(1):2001;83-91.
38. Exner T., Triplett D.A., Taberner D., Machin S.J. Guidelines for testing and revised criteria for lupus anticoagulants. SSC Subcommittee for the Standardization of Lupus Anticoagulants. Thromb. Haemost. 65(3):1991;320-322.
39. Brandt J.T., Barna L.K., Triplett D.A. Laboratory identification of lupus anticoagulants: results of the Second International Workshop for Identification of Lupus Anticoagulants. On behalf of the Subcommittee on Lupus Anticoagulants/Antiphospholipid Antibodies of the ISTH. Thromb. Haemost. 74(6):1995;1597-1603.
40. Jennings I., Kitchen S., Woods T.A., Preston F.E., Greaves M. Potentially clinically important inaccuracies in testing for the lupus anticoagulant: an analysis of results from three surveys of the UK National External Quality Assessment Scheme (NEQAS) for Blood Coagulation. Thromb. Haemost. 77(5):1997;934-937.
41. Arnout J., Meijer P., Vermylen J. Lupus anticoagulant testing in Europe: an analysis of results from the first European Concerted Action on Thrombophilia (ECAT) survey using plasmas spiked with monoclonal antibodies against human beta2-glycoprotein I. Thromb. Haemost. 81(6):1999;929-934.
42. Comparison of a standardized procedure with current laboratory practices for the detection of lupus anticoagulant in France. Working Group on Hemostasis of the Societe Francaise de Biologie Clinique. Thromb. Haemost. 70(5):1993;781-786.
43. Mannucci P.M., Canciani M.T., Mari D., Meucci P. The varied sensitivity of partial thromboplastin and prothrombin time reagents in the demonstration of the lupus-like anticoagulant. Scand. J. Haematol. 22(5):1979;423-432.
44. Brandt J.T., Triplett D.A. The effect of phospholipid on the detection of lupus anticoagulants by the dilute Russell viper venom time. Arch. Pathol. Lab. Med. 113(12):1989;1376-1378.
45. Lawrie A.S., Mackie I.J., Purdy G., Machin S.J. The sensitivity and specificity of commercial reagents for the detection of lupus anticoagulant show marked differences in performance between photo-optical and mechanical. Thromb. Haemost. 81(5):1999;758-762.
46. Gardiner C., Mackie I.J., Malia R.G., Jones D.W., Winter M., Leeming D. et al. The importance of locally derived reference ranges and standardized calculation of dilute Russell's viper venom time results in screening for lupus anticoagulant. Br. J. Haematol. 111(4):2000;1230-1235.
47. Jacobsen E.M., Barna-Cler L., Taylor J.M., Triplett D.A., Wisloff F. The evaluation of clotting times in the laboratory detection of lupus anticoagulants. Thromb. Res. 104(4):2001;275-282.
48. Schjetlein R., Wisloff F. An evaluation of two commercial test procedures for the detection of lupus anticoagulant. Am. J. Clin. Pathol. 103(1):1995;108-111.
49. Jacobsen E.M., Trettenes E.J., Strekerud F.G., Wisløff F., Abildgaard U. Lupus anticoagulant quantification in heparinized patients using addition of polybrene. Lupus. 11:2002;591.
50. Liestoel S., Wisloff F. Does subcutaneous administration of low molecular weight heparin cause false positive tests for lupus anticoagulant? Lupus. 11:2002;598.
51. Sletnes K.E., Gravem K., Wisloff F. Preparation of plasma for the detection of lupus anticoagulants and antiphospholipid antibodies. Thromb. Res. 66(1):1992;43-53.
52. Exner T. Conceptions and misconceptions in testing for lupus anticoagulants. J. Autoimmun. 15(2):2000;179-183.
53. Schjetlein R., Wisloff F. Detection of lupus anticoagulant: an evaluation of routines for preparation and storage of plasma. Thromb. Res. 79(1):1995;135-140.
54. Guidelines on testing for the lupus anticoagulant. Lupus Anticoagulant Working Party on behalf of the BCSH Haemostasis and Thrombosis Task Force. J. Clin. Pathol. 44(11):1991;885-889.
55. Exner T., Rickard K.A., Kronenberg H. A sensitive test demonstrating lupus anticoagulant and its behavioural patterns. Br. J. Haematol. 40(1):1978;143-151.
56. Alving B.M., Baldwin P.E., Richards R.L., Jackson B.J. The dilute phospholipid APTT: a sensitive assay for verification of lupus anticoagulants. Thromb. Haemost. 54(3):1985;709-712.
57. Thiagarajan P., Pengo V., Shapiro S.S. The use of the dilute Russell viper venom time for the diagnosis of lupus anticoagulants. Blood. 68(4):1986;869-874.
58. Schleider M.A., Nachman R.L., Jaffe E.A., Coleman M. A clinical study of the lupus anticoagulant. Blood. 48(4):1976;499-509.
59. Triplett D.A., Stocker K.F., Unger G.A., Barna L.K. The Textarin/Ecarin ratio: a confirmatory test for lupus anticoagulants. Thromb. Haemost. 70(6):1993;925-931.
60. Chantarangkul V., Tripodi A., Arbini A., Mannucci P.M. Silica clotting time (SCT) as a screening and confirmatory test for detection of the lupus anticoagulants. Thromb. Res. 67(4):1992;355-365.
61. Petri M., Nelson L., Weimer F., Anderson D., Darlington T., Corash L. The automated modified Russell viper venom time test for the lupus anticoagulant. J. Rheumatol. 18(12):1991;1823-1825.
62. Forastiero R.R., Cerrato G.S., Carreras L.O. Evaluation of recently described tests for detection of the lupus anticoagulant. Thromb. Haemost. 72(5):1994;728-733.
63. Liestoel S., Jacobsen E.M., Wisloff F. Dilute prothrombin time-based lupus ratio test. Integrated LA testing with recombinant tissue thromboplastin. Thromb. Res. 105:2002;177-182.
64. Greaves M., Cohen H., Machin S.J., Mackie I. Guidelines on the investigation and management of the antiphospholipid syndrome. Br. J. Haematol. 109(4):2000;704-715.
65. Jacobsen E.M., Wisloff F. False negative screening tests for lupus anticoagulants - an unrecognized problem? Thromb. Res. 82(5):1996;445-451.
66. Kaczor D.A., Bickford N.N., Triplett D.A. Evaluation of different mixing study reagents and dilution effect in lupus anticoagulant testing. Am. J. Clin. Pathol. 95:1991;408-411.
67. Rosner E., Pauzner R., Lusky A., Modan M., Many A. Detection and quantitative evaluation of lupus circulating anticoagulant activity. Thromb. Haemost. 57(2):1987;144-147.
68. Jacobsen E.M., Barna-Cler L., Taylor J.M., Triplett D.A., Wisloff F. The Lupus Ratio test - an interlaboratory study on the detection of Lupus anticoagulants by an APTT-based, integrated, and semi-quantitative test. Fifth International Survey of Lupus Anticoagulants-ISLA 5. Thromb. Haemost. 83(5):2000;704-708.
69. Triplett D.A., Brandt J.T., Kaczor D., Schaeffer J. Laboratory diagnosis of lupus inhibitors: a comparison of the tissue thromboplastin inhibition procedure with a new platelet neutralization procedure. Am. J. Clin. Pathol. 79(6):1983;678-682.
70. Schjetlein R., Sletnes K.E., Wisloff F. A quantitative, semi-automated and computer-assisted test for lupus anticoagulant. Thromb. Res. 69(2):1993;239-250.
71. Arnout J., Huybrechts E., Vanrusselt M., Vermylen J. A new lupus anticoagulant neutralization test based on platelet-derived vesicles. Br. J. Haematol. 80:1992;341-346.
72. Rauch J., Tannenbaum M., Janoff A.S. Distinguishing plasma lupus anticoagulants from anti-factor antibodies using hexagonal (II) phase phospholipids. Thromb. Haemost. 62(3):1989;892-896.
73. Brancaccio V., Ames P.R., Glynn J., Iannaccone L., Mackie I.J. A rapid screen for lupus anticoagulant with good discrimination from oral anticoagulants, congenital factor deficiency and heparin, is provided by comparing a sensitive and an insensitive APTT reagent. Blood Coagul. Fibrinolysis. 8(3):1997;155-160.
74. Rooney A.M., McNally T., Mackie I.J., Machin S.J. The Taipan snake venom time: a new test for lupus anticoagulant. J. Clin. Pathol. 47(6):1994;497-501.
75. Reber G., Roisin J.P., Migaud M., de Moerloose P. Comparison of a platelet neutralization procedure with a hexagonal phase phospholipid neutralization assay as confirmatory tests for the presence of lupus anticoagulants. Thromb. Res. 73:1994;131-135.
76. Arnout J., Vanrusselt M., Wittevrongel C., Vermylen J. Monoclonal antibodies against beta-2-glycoprotein I: use as reference material for lupus anticoagulant tests. Thromb. Haemost. 79(5):1998;955-958.
77. Harris E.N., Gharavi A.E., Patel S.P., Hughes G.R. Evaluation of the anti-cardiolipin antibody test: report of an international workshop held 4 April 1986. Clin. Exp. Immunol. 68(1):1987;215-222.
78. Coulam C.B., Mcintyre J.A., Wagenknecht D., Rote N. Interlaboratory inconsistencies in detection of anticardiolipin antibodies. Lancet. 335(8693):1990;865.
79. Reber G., Arvieux J., Comby E., Degenne D., de Moerloose P., Sanmarco M.et al. Multicenter evaluation of nine commercial kits for the quantitation of anticardiolipin antibodies. The Working Group on Methodologies in Haemostasis from the GEHT (Groupe d'Etudes sur l'Hemostase et la Thrombose). Thromb. Haemost. 73(3):1995;444-452.
80. Wasmuth J.C., Minarro D., Homrighausen A., Leifeld L., Rockstroh J.K., Sauerbruch T.et al. Phospholipid autoantibodies and the antiphospholipid antibody syndrome: diagnostic accuracy of 23 methods studied by variation in ROC curves with number of clinical manifestations. Clin. Chem. 48(7):2002;1004-1010.
81. Tincani A., Allegri F., Sanmarco M., Cinquini M., Taglietti M., Balestrieri G.et al. Anticardiolipin antibody assay: a methodological analysis for a better consensus in routine determinations - a cooperative project of the European Antiphospholipid Forum. Thromb. Haemost. 86(2):2001;575-583.
82. Tajima C., Suzuki Y., Mizushima Y., Ichikawa Y. Clinical significance of immunoglobulin A antiphospholipid antibodies: possible association with skin manifestations and small vessel vasculitis. J. Rheumatol. 25(9):1998;1730-1736.
83. Selva-O'Callaghan A., Ordi-Ros J., Monegal-Ferran F., Martinez N., Cortes-Hernandez F., Vilardell-Tarres M. IgA anticardiolipin antibodies-relation with other antiphospholipid antibodies and clinical significance. Thromb. Haemost. 79(2):1998;282-285.
84. Helbert M., Bodger S., Cavenagh J., D'Cruz D., Thomas J.M., MacCallum P. Optimising testing for phospholipid antibodies. J. Clin. Pathol. 54(9):2001;693-698.
85. Roubey R.A. Antiphospholipid syndrome: antibodies and antigens. Curr. Opin. Hematol. 7(5):2000;316-320.
86. Forastiero R.R., Martinuzzo M.E., Kordich L.C., Carreras L.O. Reactivity to beta 2 glycoprotein I clearly differentiates anticardiolipin antibodies from antiphospholipid syndrome and syphilis. Thromb. Haemost. 75(5):1996;717-720.
87. Viard J.P., Amoura Z., Bach J.F. Association of anti-beta 2 glycoprotein I antibodies with lupus-type circulating anticoagulant and thrombosis in systemic lupus erythematosus. Am. J. Med. 93(2):1992;181-186.
88. Cabral A.R., Amigo M.C., Cabiedes J., Alarcon-Segovia D. The antiphospholipid/cofactor syndromes: a primary variant with antibodies to beta 2-glycoprotein-I but no antibodies detectable in standard antiphospholipid assays. Am. J. Med. 101(5):1996;472-481.
89. Tubach F., Hayem G., Marchand J.L., Weber M., Palazzo E., de Bandt M.et al. IgG anti-beta2-glycoprotein I antibodies in adult patients with systemic lupus erythematosus: prevalence and diagnostic value for the antiphospholipid syndrome. J. Rheumatol. 27(6):2000;1437-1443.
90. Galli M., Barbui T. Antiprothrombin antibodies: detection and clinical significance in the antiphospholipid syndrome. Blood. 93(7):1999;2149-2157.
91. Donohoe S., Mackie I.J., Isenberg D., Machin S.J. Anti-prothrombin antibodies: assay conditions and clinical associations in the anti-phospholipid syndrome. Br. J. Haematol. 113(2):2001;544-549.
92. Palosuo T., Virtamo J., Haukka J., Taylor P.R., Aho K., Puurunen M.et al. High antibody levels to prothrombin imply a risk of deep venous thrombosis and pulmonary embolism in middle-aged men - a nested case-control study. Thromb. Haemost. 78(4):1997;1178-1182.
93. Vaarala O., Puurunen M., Manttari M., Manninen V., Aho K., Palosuo T. Antibodies to prothrombin imply a risk of myocardial infarction in middle-aged men. Thromb. Haemost. 75(3):1996;456-459.
94. Arvieux J., Darnige L., Caron C., Reber G., Bensa J.C., Colomb M.G. Development of an ELISA for autoantibodies to prothrombin showing their prevalence in patients with lupus anticoagulants. Thromb. Haemost. 74(4):1995;1120-1125.
95. Sugi T., Mcintyre J.A. Autoantibodies to phosphatidylethanolamine (PE) recognize a kininogen-PE complex. Blood. 86(8):1995;3083-3089.
96. Smirnov M.D., Triplett D.T., Comp P.C., Esmon N.L., Esmon C.T. On the role of phosphatidylethanolamine in the inhibition of activated protein C activity by antiphospholipid antibodies. J. Clin. Invest. 95(1):1995;309-316.
97. Karmochkine M., Cacoub P., Piette J.C., Godeau P., Boffa M.C. Antiphosphatidylethanolamine antibody as the sole antiphospholipid antibody in systemic lupus erythematosus with thrombosis. Clin. Exp. Rheumatol. 10:1992;603-605.
98. Berard M., Chantome R., Marcelli A., Boffa M.C. Antiphosphatidylethanolamine antibodies as the only antiphospholipid antibodies: I. Association with thrombosis and vascular cutaneous diseases. J. Rheumatol. 23(8):1996;1369-1374.
99. Balada E., Ordi-Ros J., Paredes F., Villarreal J., Mauri M., Vilardell-Tarres M. Antiphosphatidylethanolamine antibodies contribute to the diagnosis of antiphospholipid syndrome in patients with systemic lupus erythematosus. Scand. J. Rheumatol. 30(4):2001;235-241.
100. Mcintyre J.A., Wagenknecht D.R. Antiphospholipid antibodies. Risk assessments for solid organ, bone marrow, and tissue transplantation. Rheum. Dis. Clin. North Am. 27(3):2001;611-631.
101. von Landenberg P., Schlichting R., Schoelmerich J., Lock G. Detection of anti-phospholipid antibodies in patients with primary biliary cirrhosis and autoimmune hepatitis. Lupus. 11:2002;553.
102. Segal J.B., Lehmann H.P., Petri M., Mueller L., Kickler T.S. Testing strategies for diagnosing lupus anticoagulant: decision analysis. Am. J. Hematol. 70:2002;195-205.